Sheng D. Chen

Dong Chuan Road 800
Shanghai, 200240, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 58 publications

Reduced peripheral CD4+ memory T-cell counts mark a mortality-associated immunophenotype in anti-MDA5 dermatomyositis.

Reduced peripheral CD4+ memory T-cell counts mark a mortality-associated immunophenotype in anti-MDA5 dermatomyositis.

Journal: Frontiers in immunology

Published: June 30, 2026

Reply.

Reply.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: January 10, 2026

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience.

Correction: Obinutuzumab in systemic lupus erythematosus: a real-world experience.

Journal: Frontiers in immunology

Published: December 10, 2025

Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial.

Efficacy, safety, and completion of modified short-course rifapentine and isoniazid for latent tuberculosis infection in patients with high-risk rheumatic disease: a multicentre, open-label, randomized, non-inferiority trial.

Journal: EClinicalMedicine

Published: November 09, 2025

Obinutuzumab in systemic lupus erythematosus: a real-world experience.

Obinutuzumab in systemic lupus erythematosus: a real-world experience.

Journal: Frontiers in immunology

Published: September 10, 2025

Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.

Low-dose belimumab reduced risk of flares in patients with systemic lupus erythematosus: a multicentre, randomised, double-blind, placebo-controlled trial.

Journal: Annals of the rheumatic diseases

Published: August 07, 2025

Low-Grade Proteinuria Does Not Predict Favorable Outcomes in Lupus Nephritis: A Longitudinal Cohort Study.

Low-Grade Proteinuria Does Not Predict Favorable Outcomes in Lupus Nephritis: A Longitudinal Cohort Study.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: July 18, 2025

Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases.

Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases.

Journal: Frontiers in immunology

Published: May 08, 2025

Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis.

Rituximab vs. Cyclophosphamide induction therapy for patients with ANCA-associated vasculitis.

Journal: BMC rheumatology

Published: December 17, 2024

IL-2 signalling sustains pathogenic age-associated B cell homeostasis in lupus.

IL-2 signalling sustains pathogenic age-associated B cell homeostasis in lupus.

Journal: Annals of the rheumatic diseases

Published: December 17, 2024

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.

Journal: Clinical and translational medicine

Published: November 20, 2024

SPATS2L is a positive feedback regulator of the type I interferon signaling pathway and plays a vital role in lupus.

SPATS2L is a positive feedback regulator of the type I interferon signaling pathway and plays a vital role in lupus.

Journal: Acta biochimica et biophysica Sinica

Published: August 05, 2024

Showing 1-12 of 58

Last Updated: 09/26/2026